SCHEMBL7149019

SCHEMBL7149019

CSCc1cnc(N)nc1-c1ccco1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 16/20 0.46
ADORA1 P30542 12/20 0.46
ADORA2B P29275 2/20 0.46
MEN1 O00255 3/20 0.42
ALDH1A1 P00352 3/20 0.42
POLB P06746 3/20 0.42
MAPT P10636 3/20 0.42
ALOX15 P16050 3/20 0.42
BLM P54132 3/20 0.42
KMT2A Q03164 3/20 0.42
HSD17B10 Q99714 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HPGD P15428 2/20 0.42
PTPN7 P35236 2/20 0.42
RECQL P46063 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
PKM P14618 2/20 0.42
CASP1 P29466 2/20 0.42
CASP7 P55210 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7147816 0.76 ADORA2A (0.52) ADORA2AADORA1ADORA2BMEN1ALDH1A1
SCHEMBL1555436 0.73 ADORA2A (0.52) ADORA2AADORA1ADORA2BMEN1ALDH1A1
SCHEMBL30353572 0.73 ADORA2A (0.52) ADORA2AADORA1ADORA2BMEN1ALDH1A1
SCHEMBL7144400 0.73 ADORA2A (0.50) ADORA2AADORA1ADORA2BMEN1ALDH1A1
SCHEMBL7144862 0.73 ADORA2A (0.50) ADORA2AADORA1ADORA2BMEN1ALDH1A1
SCHEMBL4098775 0.70 ADORA2A (0.45) ADORA2AADORA1ADORA2BDHFR
SCHEMBL5241276 0.70 ADORA2B (0.50) ADORA2AADORA1ADORA2BMEN1ALDH1A1
SCHEMBL6440750 0.70 ADORA2A (0.59) ADORA2AADORA1ADORA2BMEN1ALDH1A1
SCHEMBL5467866 0.69 ADORA2B (0.52) ADORA2AADORA1ADORA2B
SCHEMBL20392752 0.68 ADORA2A (0.52) ADORA2AADORA1ADORA2BMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.